Market Overview

Meet with Selexis Scientific and Business Leaders at Several Upcoming Industry Conferences and Events

Share:

Selexis
SA
, a pioneering life sciences company and a global leader in
mammalian cell line generation technology, announced today that several
of its scientific and business leaders will be participating at upcoming
industry conferences and events, as follows:

BioJapan 2018
10 – 12 October 2018, Pacifico Yokohama,
Yokohama, Japan

Selexis team members will attend and
participate in business development and partnering activities. For more
information, please visit: https://www.ics-expo.jp/biojapan/en/

BIO-Europe 24th Annual International
Partnering Conference

5 – 7 November 2018, Bella Center
Copenhagen, Copenhagen, Denmark

Selexis team members will
attend and participate in business development and partnering
activities. For more information, please visit: https://ebdgroup.knect365.com/bioeurope/

JAACT 2018
5 – 8 November 2018, Tsukuba International
Congress Center, Tsukuba, Japan

Selexis
Chief Executive Officer Igor Fisch, PhD
, will present, "Selexis Cell
Line Development Platform, and Technologies for Assessment of Cell Line
Integrity and Clonality," followed by a joint Selexis/KBI presentation
titled, "GENE to GMP in 9 Months – Accelerating the Development of
Innovative Discoveries into Life-Changing Biological Medicines."
Additionally, Selexis will have representation at the JSR booth in the
exhibit hall. For more information, please visit: https://www.aeplan.co.jp/jaact2018/index.html

10th Annual PEGS Europe Protein & Antibody
Engineering Summit

12 – 16 November 2018, Lisbon Congress
Center, Lisbon, Portugal

Selexis
Chief Executive Officer Igor Fisch, PhD
, will present "Selexis' SUREscan
and SUREsignature: Technologies for Assessment of Cell Line
Integrity and Clonality" on Wednesday, 14 November at 10:05 a.m. WET.
Additionally, Selexis is a conference sponsor and exhibitor (booth
#310). For more information, please visit: http://www.pegsummiteurope.com/

Antibody Engineering & Therapeutics
9 – 13 December
2018, Manchester Grand Hyatt San Diego, San Diego, CA

Selexis
team members will attend the conference. For more information, please
visit: https://lifesciences.knect365.com/antibody-engineering-therapeutics/

About Selexis SA

Selexis SA is the global leader in cell line development with
best-in-class modular technology and highly specialized solutions that
enable the life sciences industry to rapidly discover, develop and
commercialize innovative medicines and vaccines. Our global partners are
utilizing Selexis technologies to advance more than 100 drug products in
clinical development and the manufacture of three commercial products.
As part of a comprehensive drug development process, the Company's
technologies shorten development timelines and reduce manufacturing
risks. In June 2017, Selexis became part of the JSR Life Sciences group.
JSR's CDMO service offering leverages the full capabilities of Selexis'
proprietary SUREtechnology Platform™ to offer an end-to-end
solution to industry. More information is available at www.selexis.com.

FOR MORE INFORMATION

- Web www.selexis.com
-
LinkedIn
www.linkedin.com/company/selexis-sa
-
Twitter
www.twitter.com/SelexisSA
-
Facebook
www.facebook.com/SelexisSA

View Comments and Join the Discussion!